Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aprepitant for CINV in Adolescents
NCT00080444Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Apr 2004
- Primary completion
- Sep 2006
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of aprepitant in chemotherapy-induced nausea and vomiting (CINV) (3 arms), sponsored by Merck & Co. Primary endpoint: Percentage of Participants Who Experience Study-drug-related Adverse Events (Cycle 1). Started Apr 2004; status: completed.
02
Drugs
aprepitant
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on NCT00080444.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00080444.